Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$109.42M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$110.05M
Gross Margin
46.49%
TTM Avg
23.25%
3Y Avg
11.62%
5Y Avg
7.75%
Market Cap
$109.07M
Gross Margin
33.94%
TTM Avg
48.53%
3Y Avg
56.75%
5Y Avg
59.91%
Market Cap
$108.29M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
2.35%
Market Cap
$107.44M
Gross Margin
99.54%
TTM Avg
49.77%
3Y Avg
24.89%
5Y Avg
16.59%
Market Cap
$107.28M
Gross Margin
83.37%
TTM Avg
83.81%
3Y Avg
82.64%
5Y Avg
80.50%
Market Cap
$113.30M
Gross Margin
99.91%
TTM Avg
-67.10%
3Y Avg
-31.47%
5Y Avg
-20.98%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $109.42M | 0.00% | 0.00% | 0.00% | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $110.05M | 46.49% | 23.25% | 11.62% | 7.75% |
| Apyx Medical Corporation (APYX)vs › | $109.07M | 33.94% | 48.53% | 56.75% | 59.91% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.29M | 0.00% | 0.00% | 0.00% | 2.35% |
| Immunic, Inc. (IMUX)vs › | $107.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| BGM Group Ltd. (BGM)vs › | $111.14M | 12.79% | 14.59% | 10.64% | 11.25% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.44M | 99.54% | 49.77% | 24.89% | 16.59% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.28M | 83.37% | 83.81% | 82.64% | 80.50% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.30M | 99.91% | -67.10% | -31.47% | -20.98% |
| Definitive Healthcare Corp. (DH)vs › | $105.48M | 71.67% | 77.09% | 79.04% | 77.65% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
